Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
AEON Biopharma, Inc.: Amended the contractual expiration date for completing a business combination from February 11, 2023 to August 11, 2023 (effective 2023-02-10).
- Change
- charter amendment
- Effective
- 2023-02-10
Exact text from the filing
the certificate of amendment to the second amended and restated certificate of incorporation (the “Charter Amendment”) to amend the Company’s contractual expiration date of February 11, 2023 by changing the date by which the Company must cease all operations except for the purpose of winding up if it fails to complete a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination (a “Business Combination”) from February 11, 2023 to August 11, 2023
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AEON Biopharma, Inc. shareholders approved To amend the second amended and restated certificate of incorporation to extend the date by which the Company must consummate a business combination from February 11, 2023 to August 11, 2023. at the 2023-02-11 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-02-11
Exact text from the filing
Proposal No. 1 – The Extension Amendment – to amend the Company’s second amended and restated certificate of incorporation to extend the date by which the Company must consummate a business combination from February 11, 2023 (the date which is 24 months from the closing date of the Company’s initial public offering of shares of Class A common stock) to August 11, 2023 (the date which is 30 months from the closing date of the initial public offering). For Against Abstain 24,548,209 3,245,246 2,463
View on SEC.gov